Ultima-Tesamorelin: Compound Profile
Tesamorelin acetate is a synthetic growth hormone releasing hormone analogue that represents a significant advancement in peptide research. This 44-amino acid compound demonstrates high affinity for GHRH receptors, making it valuable for studying growth hormone secretion mechanisms in laboratory settings. Researchers at Stroid UK Shop frequently investigate tesamorelin’s properties as part of comprehensive endocrine research programmes examining hypothalamic-pituitary axis function.
Laboratory Applications
In research environments, scientists examine tesamorelin acetate’s interaction with GHRH receptors and its influence on growth hormone pulsatility patterns. The compound enables detailed investigation of circadian rhythm effects on hormone secretion and cellular signalling cascades. Studies often incorporate tesamorelin alongside other research compounds from our growth hormone research collection to evaluate synergistic mechanisms. Research protocols frequently compare tesamorelin’s activity profile with other secretagogues available in our SARMs catalogue and complementary compounds from our peptides section to understand broader endocrine modulation pathways.
Technical Specifications
| Parameter | Value |
|---|---|
| Chemical Name | Tesamorelin Acetate |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | 5135.8 g/mol |
| Sequence Length | 44 amino acids |
| Purity | ≥98% HPLC verified |
| Form | Lyophilised powder |
| Vial Content | 2mg per vial |
| Storage | -20°C protected from light |
Research Compliance Statement
This tesamorelin acetate preparation is manufactured exclusively for in-vitro laboratory research applications and scientific investigation purposes. The compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure proper laboratory protocols, appropriate safety measures, and institutional approval before conducting studies. All investigations should comply with relevant research guidelines and institutional review board requirements where applicable.
